The post Superconvergence of Biotechnology, AI, and Cloud Computing: Revolutionizing Medicine in 2024 appeared on BitcoinEthereumNews.com.

In a remarkable display of the convergence of megatrends, the year 2024 witnesses groundbreaking advancements in medicine, particularly in personalized cancer therapy. Moderna, renowned for its rapid development of the COVID-19 mRNA vaccine, is at the forefront of this revolution, leveraging AI, genetics, and cloud computing to offer hope to late-stage melanoma patients. This convergence is shaping the future of healthcare and has the potential to save countless lives. Personalized cancer therapy: A triumph of technology Late in 2023, Moderna reported astounding results from an ongoing early-stage trial for a personalized therapy aimed at combating late-stage melanoma, a notoriously lethal form of skin cancer. CEO Stephane Bancel unveiled the innovative approach, describing how the company harnessed the power of AI analytics and massive cloud computing to sequence DNA data from cancerous and healthy cells. By comparing the genetic codes, Moderna’s algorithm identifies unique elements in cancer cells that could serve as targets for a patient’s immune system. This information enables the creation of a personalized cancer vaccine, administered using mRNA technology similar to COVID-19 vaccines, effectively training the patient’s immune system to attack the specific cancer. Remarkably, this tailored cancer therapy can be prepared within just 30 days of extracting and sequencing the patient’s cells. After three years of trials, this therapy, known as mRNA-4157, when combined with Merck’s Keytruda, reduced the risk of recurrence or death by 49% in late-stage melanoma patients compared to Keytruda alone. The combination also decreased the risk of developing distant metastasis or death by 62%. These results offer hope for patients facing dire prognoses and hint at a medical future once considered science fiction. The superconvergence of BioRevolution, AI, and cloud computing This groundbreaking achievement is a testament to what Jamie Metzl, partner at WisdomTree BioRevolution ETF, calls “superconvergence.” It represents the intersection of…

---

Filed under: News - @ January 1, 2024 8:24 am